{
    "clinical_study": {
        "@rank": "9892", 
        "brief_summary": {
            "textblock": "Iron overload is a leading cause of morbidity and mortality in transfusion-dependent\n      patients. Deferasirox is the most promising iron chelator agent in several clinical\n      scenarios. The investigators propose a retrospective study (chart review) to evaluate\n      comprehensive iron overload management in transfusion-dependent patients treated with\n      deferasirox for up to 5-10 years in a real clinical practice setting."
        }, 
        "brief_title": "Retrospective Evaluation of Adult and Pediatric Transfusion-dependent Patients Treated With Deferasirox Therapy", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Iron Overload", 
        "condition_browse": {
            "mesh_term": "Iron Overload"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Transfusion- dependent patients (> 2 years);\n\n          -  Ongoing deferasirox therapy during the study period;\n\n          -  \u2265 2 Magnetic Resonance scans (one at baseline and at least one post baseline - as per\n             clinical need) during study period (this criteria is not mandatory for patients\n             undergoing only the endocrine subanalysis and participating only to the cardiac\n             analysis);\n\n          -  Available medical history including relevant clinical and laboratory data (e.g serum\n             ferritin, liver function tests, renal function tests, endocrine parameters ) at\n             baseline before starting deferasirox treatment\n\n        Exclusion Criteria:\n\n          -  Non transfusion- dependent patients;\n\n          -  Other chelation therapy than deferasirox;\n\n          -  Absence of complete medical history as above specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "2 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Adult and pediatric transfusion- dependent patients (male and female) with different\n        underlying cronic anemias who received iron chelation therapy with deferasirox during the\n        observational study period and underwent at least 2 cardiac MRI scans at the Pozzuoli\n        site.\n\n        All consecutive patients visited at the participating sites starting from March 2003 to\n        October 2012  will be entered in this observational study (chart review) provided all the\n        inclusion an no exclusion criteria are met."
            }
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01874405", 
            "org_study_id": "DIPEDNA-2013-1"
        }, 
        "intervention_browse": {
            "mesh_term": "Deferasirox"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Iron overload", 
            "thalassaemia", 
            "deferasirox", 
            "magnetic resonance", 
            "endocrine function"
        ], 
        "lastchanged_date": "June 6, 2013", 
        "number_of_groups": "1", 
        "official_title": "Effectiveness of Deferasirox Therapy on Comprehensive Management of Iron Overload in Adult and Pediatric Transfusion-dependent Patients: a Long Term Retrospective Study", 
        "overall_official": {
            "affiliation": "Second University of Naples", 
            "last_name": "Silverio Perrotta, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "change from baseline to end of study in cardiac T2*, as measured by Magnetic Resonance, in patients with iron overload (cardiac T2* <20 ms at baseline)", 
                "measure": "cardiac T2* in patients treated with deferasirox", 
                "safety_issue": "No", 
                "time_frame": "at least 1 year"
            }, 
            {
                "description": "maintenance from baseline to end of study of cardiac T2* in not iron overloaded patients (cardiac T2* >20 ms at baseline)", 
                "measure": "cardiac T2* in patients treated with deferasirox", 
                "safety_issue": "No", 
                "time_frame": "at least 1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01874405"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Second University of Naples", 
            "investigator_full_name": "Silverio Perrotta", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "change in left and right ejection fraction, telediastolic and telesystolic volumes, stroke volumes, cardiac output, myocardial mass, measured by Cardiac Magnetic Resonance, from baseline to end of study", 
                "measure": "cardiac function in patient undergoing deferasirox treatment", 
                "safety_issue": "No", 
                "time_frame": "at least 1 year"
            }, 
            {
                "measure": "change in liver iron concentration", 
                "safety_issue": "No", 
                "time_frame": "at least 1 year"
            }, 
            {
                "description": "Thyroid function (TSH, free triiodothyronine and free thyroxine serum free T4 levels), pancreatic cell function (basal glycemia, glycated hemoglobin level), bone mineral density (z-score) will be evaluated by the closest assessment to baseline (first deferasirox exposure) and to the end of study", 
                "measure": "maintenance of normal endocrine function in patients without endocrine dysfunction and improvement in disease severity in patients affected by endocrine dysfunction from baseline to end of study", 
                "safety_issue": "No", 
                "time_frame": "at least 3 years"
            }
        ], 
        "source": "Second University of Naples", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Second University of Naples", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2003", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "June 2013"
    }
}